Research summary, original research, 2026

Occupational Pelvic and Chest-Level Radiation Exposure Among Interventional Echocardiographers During Percutaneous Structural Heart Interventions

Wessly P, Haines J, Jimenez E, Howard L, Madalinski B, Jain R. JACC. Advances. 2026

Read the original paper

In plain language

In 230 structural heart procedures at one US center, under-lead pelvic dose to interventional echocardiographers was almost always undetectable. Chest-level dose was higher in mitral and tricuspid cases, and was associated with half-shield-only use and head-of-bed positioning.

At a glance

Type of study
Original research, Dosimetry measurement study
Who was studied
Other physicians, Mixed lab staff
Size
n = 230 procedures
Where
United States
Summary based on
the full text

What it found

  • Under-lead pelvic dose was undetectable in nearly all procedures. The modeled fetal dose over a full pregnancy was far below the International Commission on Radiological Protection (ICRP) 1 mSv limit.

    Key figures: 0 μSv in 98.7% of cases; ∼2.3 μSv estimated for full pregnancy

  • Half-shield-only use was independently associated with higher chest-level dose than adjustable full or combination shielding. This was the largest effect in the model.

    Key figures: adjusted fold change 3.78; 95% confidence interval (CI): 1.51-9.44; P = 0.005

  • Chest-level dose to interventional echocardiographers rose from left atrial appendage occlusion (LAAO) to mitral to tricuspid interventions.

    Key figures: median 9.0 μSv (IQR: 3.2-21.0) LAAO, 18.0 μSv (7.5-43.5) TMVI, 36.0 μSv (16-116) TTVI; P < 0.001

  • Head-of-bed positioning was independently associated with about twofold higher chest-level dose. The estimate rests on few cases.

    Key figures: adjusted fold change 2.17; 95% CI: 1.06-4.43; P = 0.035, n = 17

  • Interventional echocardiographers received much higher chest-level doses than sonographers during the same procedures.

    Key figures: 10- to 50-fold higher; P < 0.001

Limits to keep in mind

Single-center observational study using one upper-arm dosimeter site, with no eye, thyroid or hand dosimetry, two fluoroscopy systems, few head-of-bed cases (n = 17) and no correction for multiple comparisons. The fetal dose is a modeled estimate from a suprapubic under-lead dosimeter, not a measured fetal dose.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.